Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

61. Impact of neuromuscular electrical stimulation on functional capacity of patients with chronic kidney disease on hemodialysis. Full Text available with Trip Pro

Impact of neuromuscular electrical stimulation on functional capacity of patients with chronic kidney disease on hemodialysis. Literature shows that patients undergoing hemodialysis present poor physical conditioning and low tolerance to exercise. They may also suffer from respiratory dysfunctions. The purpose of this study was to evaluate the effects of neuromuscular electrical stimulation on pulmonary function and functional capacity of patients with chronic kidney disease (...) on hemodialysis.Forty adult patients with chronic kidney disease on hemodialysis were prospectively studied and randomized into two groups (control n = 20 and treatment n = 20). The treatment group underwent bilateral femoral quadriceps muscles electrical stimulation for 30 minutes during hemodialysis, three times per week, for two months. The patients were evaluated by pulmonary function test, maximum respiratory pressures, maximum one-repetition test, and six-minute walk test (6MWT), before and after

2018 Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia Controlled trial quality: uncertain

62. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease Full Text available with Trip Pro

Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease Hyperkalaemia risk precludes optimal renin-angiotensin-aldosterone system inhibitor use in patients with heart failure (HF), particularly those with chronic kidney disease (CKD). Patiromer is a sodium-free, non-absorbed potassium (K+ )-binding polymer approved for the treatment of hyperkalaemia. In PEARL-HF, patiromer 25.2 g (fixed dose (...) ) prevented hyperkalaemia in HF patients with or without CKD initiating spironolactone. The current study evaluated the effectiveness of a lower starting dose of patiromer (16.4 g/day) followed by individualized titration in preventing hyperkalaemia and hypokalaemia when initiating spironolactone.This open-label 8-week study enrolled 63 patients with CKD, serum K+ 4.3-5.1 mEq/L, and chronic HF, who, based on investigator opinion, should receive spironolactone. Eligible patients started spironolactone 25

2018 ESC heart failure Controlled trial quality: uncertain

63. Cathepsin S As an Inhibitor of Cardiovascular Inflammation and Calcification in Chronic Kidney Disease Full Text available with Trip Pro

Cathepsin S As an Inhibitor of Cardiovascular Inflammation and Calcification in Chronic Kidney Disease Cardiovascular disease (CVD) is responsible for the majority of deaths in the developed world. Particularly, in patients with chronic kidney disease (CKD), the imbalance of calcium and phosphate may lead to the acceleration of both vascular and valve inflammation and calcification. One in two patients with CKD are reported as dying from cardiovascular causes due to the resulting acceleration (...) in the development of atherosclerosis plaques. In addition, CKD patients on hemodialysis are prone to aortic valve calcification and often need valve replacement before kidney transplantation. The lysosomal proteases, cathepsins, are composed of 11 cysteine members (cathepsin B, C, F, H, K, L, O, S, V, W, and Z), as well as serine proteases cathepsin A and G, which cleave peptide bonds with serine as the amino acid, and aspartyl proteases D and E, which use an activated water molecule bound to aspartate to break

2018 Frontiers in cardiovascular medicine

64. Renal Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation: Involvement of Chronic Graft-Versus-Host Disease Full Text available with Trip Pro

Renal Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation: Involvement of Chronic Graft-Versus-Host Disease 29854984 2019 02 26 2468-0249 3 3 2018 May Kidney international reports Kidney Int Rep Renal Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation: Involvement of Chronic Graft-Versus-Host Disease. 743-747 10.1016/j.ekir.2017.12.013 Mii Akiko A Department of Nephrology, Nippon Medical School, Tokyo, Japan. Shimizu Akira A Department of Analytic (...) Human Pathology, Nippon Medical School, Tokyo, Japan. Kaneko Tomohiro T Department of Nephrology, Nippon Medical School, Tokyo, Japan. Nakayama Kazutaka K Department of Hematology, Nippon Medical School, Tokyo, Japan. Yamaguchi Hiroki H Department of Hematology, Nippon Medical School, Tokyo, Japan. Tsuruoka Shuichi S Department of Nephrology, Nippon Medical School, Tokyo, Japan. eng Case Reports 2018 01 05 United States Kidney Int Rep 101684752 2468-0249 2018 6 2 6 0 2018 6 2 6 0 2018 6 2 6 1

2018 Kidney international reports

65. Protective effects of hydrogen sulfide on chronic kidney disease by reducing oxidative stress, inflammation and apoptosis Full Text available with Trip Pro

Protective effects of hydrogen sulfide on chronic kidney disease by reducing oxidative stress, inflammation and apoptosis The current study aimed to examine the renoprotective effects of long-term treatment with sodium hydrosulfide (NaHS), a prominent hydrogen sulfide donor, in 5/6 nephrectomy animal model. Twenty-four rats were randomly divided into 3 groups including sham-operated group (Sham), 5/6-nephrectomized group (5/6 Nx), and NaHS-treated group (5/6Nx+NaHS). NaHS (30 micromol/l (...) ) was added twice daily into the drinking water and renal failure was induced by 5/6 nephrectomy. Twelve weeks after surgical procedure, blood pressure, creatinine clearance (CCr), urine concentration of neutrophil gelatinase associated lipocalin (NGAL) and tissue concentration of malondialdehyde (MDA), superoxide dismutase (SOD), as well as renal morphological changes, apoptosis (cleaved caspase-3) and inflammation (p-NF-κB) were measured. Five-sixth nephrectomy induced severe renal damage as indicated

2018 EXCLI journal

66. Management of Chronic Kidney Disease

with diabetes mellitus and/or hypertension should be screened at least yearly for chronic kidney disease (CKD). • Screening for CKD may be considered for patients with: ? age >65 years old ? obesity ? cardiovascular disease ? metabolic syndrome ? drugs e.g. nephrotoxic drugs, long-term use of proton-pump inhibitors or analgesics ? family history of CKD or hereditary kidney disease ? gout ? multisystem diseases with potential kidney involvement e.g. systemic lupus erythematosus ? structural renal tract (...) Reviewers x Algorithm 1 Screening and Investigations for xi Chronic Kidney Disease in Adults with Diabetes Algorithm 2 Screening and Investigations for xii Chronic Kidney Disease in Adults without Diabetes Algorithm 3 Evaluation of Haematuria in xiii Chronic Kidney Disease in Adults Algorithm 4 Treatment for Chronic Kidney Disease xiv in Adults 1. INTRODUCTION 1 2. RISK FACTORS 2 3 ASSESSMENT 4 3.1 Screening 4 3.2 Renal Function 6 3.3 Renal Ultrasound 7 3.4 Classification 8 4. INTERVENTIONS IN DELAYING

2018 Ministry of Health, Malaysia

67. Comparison of Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Chronic Kidney Disease (Abstract)

Comparison of Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Chronic Kidney Disease There are few data comparing outcomes of transcatheter aortic valve implantation (TAVI) with surgical aortic valve replacement (SAVR) in patients with chronic kidney disease. In this retrospective cohort study using the National Inpatient Sample 2011 to 2014, we included a total of 2,820 TAVI and 4,054 SAVR procedures, representative of 14,039 TAVI and 19,835 SAVR procedures (...) ) compared with SAVR. In conclusion, TAVI may be a preferable approach to SAVR in patients with severe aortic stenosis in the setting of chronic kidney disease.Copyright © 2017 Elsevier Inc. All rights reserved.

2018 EvidenceUpdates

68. Lanthanum carbonate and sevelamer carbonate for hyperphosphataemia in patients with chronic kidney disease

Lanthanum carbonate and sevelamer carbonate for hyperphosphataemia in patients with chronic kidney disease '); } else { document.write(' '); } ACE | Lanthanum carbonate and sevelamer carbonate for treating hyperphosphataemia in patients with chronic kidney disease Search > > Lanthanum carbonate and sevelamer carbonate for treating hyperphosphataemia in patients with chronic kidney disease - Lanthanum carbonate and sevelamer carbonate for treating hyperphosphataemia in patients with chronic (...) kidney disease Published on 1 October 2018 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has recommended: Sevelamer carbonate 800 mg tablet for the treatment of hyperphosphataemia in patients with chronic kidney disease who: have persistent hyperphosphataemia despite optimising treatment with calcium-based phosphate binders; or cannot tolerate calcium-based phosphate binders due to hypercalcaemia. Subsidy status Sevelamer carbonate 800 mg tablet is recommended

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

69. Whole-Exome Sequencing in Adults With Chronic Kidney Disease: A Pilot Study. Full Text available with Trip Pro

Whole-Exome Sequencing in Adults With Chronic Kidney Disease: A Pilot Study. The utility of whole-exome sequencing (WES) for the diagnosis and management of adult-onset constitutional disorders has not been adequately studied. Genetic diagnostics may be advantageous in adults with chronic kidney disease (CKD), in whom the cause of kidney failure often remains unknown.To study the diagnostic utility of WES in a selected referral population of adults with CKD.Observational cohort.A major academic (...) syndrome characterized by lung, bone marrow, and liver fibrosis; these findings extend the phenotype of PARN mutations to renal fibrosis. In addition, review of the American College of Medical Genetics actionable genes identified a pathogenic BRCA2 mutation in a proband who was diagnosed with breast cancer on follow-up. The results affected clinical management in most identified cases, including initiation of targeted surveillance, familial screening to guide donor selection for transplantation

2017 Annals of Internal Medicine

70. Derivation and External Validation of Prediction Models for Advanced Chronic Kidney Disease Following Acute Kidney Injury. Full Text available with Trip Pro

Derivation and External Validation of Prediction Models for Advanced Chronic Kidney Disease Following Acute Kidney Injury. Some patients will develop chronic kidney disease after a hospitalization with acute kidney injury; however, no risk-prediction tools have been developed to identify high-risk patients requiring follow-up.To derive and validate predictive models for progression of acute kidney injury to advanced chronic kidney disease.Data from 2 population-based cohorts of patients (...) validated with data from a cohort of 2761 patients hospitalized in Ontario, Canada (June 2004-March 2012, with follow-up to March 2013).Demographic, laboratory, and comorbidity variables measured prior to discharge.Advanced chronic kidney disease was defined by a sustained reduction in eGFR less than 30 mL/min/1.73 m2 for at least 3 months during the year after discharge. All participants were followed up for up to 1 year.The participants (mean [SD] age, 66 [15] years in the derivation and internal

2017 JAMA

71. Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial. Major depressive disorder (MDD) is prevalent among patients with chronic kidney disease (CKD) and is associated with morbidity and mortality. The efficacy and adverse events of selective serotonin reuptake inhibitors in these patients are unknown.To determine whether treatment with sertraline improves depressive symptoms in patients with CKD (...) and MDD.The Chronic Kidney Disease Antidepressant Sertraline Trial (CAST) was a randomized, double-blind, placebo-controlled trial involving 201 patients with stage 3, 4, or 5 non-dialysis-dependent CKD, who were enrolled at 3 US medical centers. The Mini Neuropsychiatric Interview was used to establish MDD. The first participant was randomized in March 2010 and the last clinic visit occurred in November 2016.After a 1-week placebo run-in, participants were randomized to sertraline (n = 102) for 12 weeks

2017 JAMA Controlled trial quality: predicted high

72. Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries Full Text available with Trip Pro

Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries Kidney biopsies to elucidate the cause of chronic kidney disease (CKD) are performed in a minority of persons with CKD living in high-income countries, since associated conditions-that is, diabetes mellitus, vascular disease or obesity with pre-diabetes, prehypertension or dyslipidaemia-can inform (...) as reference. In the USA, urban India and Moldova, 79.0%-83.9%; in China and Nepal, 62.4%-66.7% and in Nigeria, 51.6% persons with CKD fit one of three established risk profiles. Diabetes was most common in urban India and vascular disease in Moldova (50.7% and 33.2% of persons with CKD in urban India and Moldova, respectively). In Nigeria, 17.8% of persons with CKD without established risk factors had albuminuria ≥300 mg/g, the highest proportion in any country. While the majority of persons with CKD

2017 BMJ global health

73. Afshinnia F, Rajendiran TM, Karnovsky A, et al. Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort. Kidney Int Rep. 2016;1:256–268 Full Text available with Trip Pro

Afshinnia F, Rajendiran TM, Karnovsky A, et al. Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort. Kidney Int Rep. 2016;1:256–268 [This corrects the article DOI: 10.1016/j.ekir.2016.08.007.].

2017 Kidney international reports

74. A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease Full Text available with Trip Pro

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease To present a long-term policy model of cardiovascular disease (CVD) in moderate-to-advanced chronic kidney disease (CKD).A Markov model with transitions between CKD stages (3B, 4, 5, on dialysis, with kidney transplant) and cardiovascular events (major atherosclerotic events, haemorrhagic stroke, vascular death) was developed with individualised CKD and CVD risks estimated using the 5 years' follow-up data (...) of the 9270 patients with moderate-to-severe CKD in the Study of Heart and Renal Protection (SHARP) and multivariate parametric survival analysis. The model was assessed in three further CKD cohorts and compared with currently used risk scores.Higher age, previous cardiovascular events and advanced CKD were the main contributors to increased individual disease risks. CKD and CVD risks predicted by the state-transition model corresponded well to risks observed in SHARP and external cohorts. The model's

2017 EvidenceUpdates

75. Hypertensive Kidney Injury and the Progression of Chronic Kidney Disease Full Text available with Trip Pro

Hypertensive Kidney Injury and the Progression of Chronic Kidney Disease 28760941 2018 01 29 2018 11 13 1524-4563 70 4 2017 10 Hypertension (Dallas, Tex. : 1979) Hypertension Hypertensive Kidney Injury and the Progression of Chronic Kidney Disease. 687-694 10.1161/HYPERTENSIONAHA.117.08314 Griffin Karen A KA From the Hines VA Hospital, IL; and Loyola University Medical Center, Maywood, IL. kgriffi@lumc.edu. eng R01 DK040426 DK NIDDK NIH HHS United States R01 DK061653 DK NIDDK NIH HHS United (...) States Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Review 2017 07 31 United States Hypertension 7906255 0194-911X IM Disease Progression Humans Hypertension complications physiopathology Renal Insufficiency, Chronic etiology physiopathology 2017 8 2 6 0 2018 1 30 6 0 2017 8 2 6 0 ppublish 28760941 HYPERTENSIONAHA.117.08314 10.1161/HYPERTENSIONAHA.117.08314 PMC5599324 NIHMS891429 Curr Opin Nephrol Hypertens. 2012 Jan;21(1):1-6 22048724 Hypertension

2017 Hypertension (Dallas, Tex. : 1979)

76. Altered Protein Composition of Subcutaneous Adipose Tissue in Chronic Kidney Disease Full Text available with Trip Pro

Altered Protein Composition of Subcutaneous Adipose Tissue in Chronic Kidney Disease Loss of renal function is associated with high mortality from cardiovascular disease (CVD). Patients with chronic kidney disease (CKD) have altered circulating adipokine and nonesterified fatty acid concentrations and insulin resistance, which are features of disturbed adipose tissue metabolism. Because dysfunctional adipose tissue contributes to the development of CVD, we hypothesize that adipose tissue

2017 Kidney international reports

77. Estimating One-Year Risk of Incident Chronic Kidney Disease: Retrospective Development and Validation Study Using Electronic Medical Record Data From the State of Maine Full Text available with Trip Pro

Estimating One-Year Risk of Incident Chronic Kidney Disease: Retrospective Development and Validation Study Using Electronic Medical Record Data From the State of Maine Chronic kidney disease (CKD) is a major public health concern in the United States with high prevalence, growing incidence, and serious adverse outcomes.We aimed to develop and validate a model to identify patients at risk of receiving a new diagnosis of CKD (incident CKD) during the next 1 year in a general population.The study

2017 JMIR medical informatics

78. Management of Severe Hyponatremia With a Custom Continuous Renal Replacement Therapy in an Infant With Newly Diagnosed Chronic Kidney Disease Full Text available with Trip Pro

Management of Severe Hyponatremia With a Custom Continuous Renal Replacement Therapy in an Infant With Newly Diagnosed Chronic Kidney Disease 29270536 2019 02 26 2468-0249 2 6 2017 Nov Kidney international reports Kidney Int Rep Management of Severe Hyponatremia With a Custom Continuous Renal Replacement Therapy in an Infant With Newly Diagnosed Chronic Kidney Disease. 1254-1258 10.1016/j.ekir.2017.07.003 Gaudreault-Tremblay Marie-Michèle MM Division of Nephrology, The Hospital for Sick (...) of Toronto, Toronto, Ontario, Canada. Lemaire Mathieu M Division of Nephrology, The Hospital for Sick Children, Toronto, Ontario, Canada. Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada. eng Case Reports 2017 07 20 United States Kidney Int Rep 101684752 2468-0249 2017 12 23 6 0 2017 12 23 6 0 2017 12 23 6 1 epublish 29270536 10.1016/j.ekir.2017.07.003 S2468-0249(17)30301-7 PMC5733878 J Am Soc Nephrol. 2012 Jul;23(7):1140-8 22626822 Pediatr Nephrol. 2010 Jul;25(7):1225-38

2017 Kidney international reports

79. Serum Potassium Levels and Risk of Sudden Cardiac Death Among Patients With Chronic Kidney Disease and Significant Coronary Artery Disease Full Text available with Trip Pro

Serum Potassium Levels and Risk of Sudden Cardiac Death Among Patients With Chronic Kidney Disease and Significant Coronary Artery Disease Chronic kidney disease (CKD) patients have increased risks of sudden cardiac arrest and sudden cardiac death (SCA/SCD) that are not explained by traditional risk factors. We examined associations between serum potassium and SCA/SCD in a large cohort of patients with coronary artery disease (CAD) and moderate CKD.Among 22,009 patients who underwent cardiac (...) catheterization at our institution between 1999 and 2011, 6181 patients had an estimated glomerular filtration rate of ≤60 ml/min per 1.73 m2 and were not receiving renal replacement therapy. The risk of SCA/SCD and all-cause mortality associated with potassium concentration was evaluated at the time of cardiac catheterization (baseline) and most proximate to SCA/SCD events. Covariate-adjusted Cox models were used to examine relationships between baseline potassium measurements and outcomes. A propensity

2017 Kidney international reports

80. Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure Full Text available with Trip Pro

Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure This study investigated the relationship between the initial diuretic response to tolvaptan and clinical predictors for tolvaptan responders in patients with acute decompensated heart failure (ADHF).Patients (153) with ADHF (clinical scenario 2 or 3 with signs of fluid retention) who were administered tolvaptan were enrolled. Tolvaptan (15 or 7.5 mg) was administered for at least 7 days (...) to those patients in whom fluid retention was observed even after standard treatment. The maximum urine volume immediately after tolvaptan administration showed good correlations with the ejection fraction and estimated glomerular filtration rate that were independent predictors of the urine volume (UV) responders (≥1500 mL increase in urine volume). The diuretic response (in terms of maximum diuresis) diminished with advancing chronic kidney disease (CKD) stage and concomitant deterioration

2017 ESC heart failure